**North America Osteoporosis Treatment Market: Celltrion Healthcare Co., Ltd. Commences Phase 1 Trial of Denosumab Biosimilar to Amplify its Market Position** The North America osteoporosis treatment market size is expected to gain momentum by reaching USD 8.29 billion by 2027 while exhibiting a CAGR of 6.6% between 2020 and 2027. This is attributable to the increasing prevalence of osteoporosis and the growing number of government approvals for the therapeutic drugs that are propelling the demand in the North America osteoporosis treatment options. Fortune Business Insights in its latest report, titled, “North America Osteoporosis Treatment Market Size, Share &Covid-19 Impact Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral); By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies), 2020-2027.”, mentions that the market stood at USD 5.18 billion in 2019. Request Sample PDF Request a Sample - Osteoporosis Treatment Market Size, Share and Global Industry Trend Forecast till 2025 (https://www.fortunebusinessinsights.com/enquiry/sample/osteoporosis-treatment-market-101034) COVID-19 Impact: Market to Experience a Sluggish Growth at 2.3% CAGR in 2020 The COVID-19 pandemic has led to the healthcare systems and hospitals to divert their complete focus on treating people suffering from the disease. In contrast, several elective medical procedures and osteoporosis treatment appointments have either been canceled or postponed. Based on our analysis, the market will exhibit aslow growth at 2.3% CAGR in 2020 due to the aforementioned reasons. However, the market will return to normalcy once the pandemic is over. Osteoporosis is a type of medical condition that occurs when the bone synthesis gets interrupted and if left unattended, often may lead to a fracture. In addition to this, the condition leads to brittle and lower density of bones and is mostly common in the older population, along with women. ***COMPETITIVE LANDSCAPE*** **Collaboration between Eminent Companies to Brighten Their Market Positions** The market for North America is experiencing proactive competition between major companies that are collaborating with other companies to expand their product portfolio and boost sales revenue. Furthermore, other key players are adopting organic and inorganic strategies such as partnership, the introduction of novel products, and merger and acquisition that will bode well for the growth of the market for North America. Major companies in the Global North America Osteoporosis Treatment Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the North America Osteoporosis Treatment Industry. https://www.fortunebusinessinsights.com/enquiry/customization/osteoporosis-treatment-market-101034***Industry Development:*** · **August 2020** - Celltrion Healthcare Co., Ltd commenced the Phase 1 trial of Denosumab Biosimilar, a monoclonal antibody injection adopted in the management of osteoporosis. The company has invested in R&D to develop novel therapeutics solutions for the treatment of the disease. ***List of the Companies Profiled in the Market:*** · AbbVie Inc. (North Chicago, Illinois, U.S.) · Eli Lilly and Company (Indianapolis, Indiana, U.S.) · Amgen Inc. (Thousand Oaks, California, U.S.) · F. Hoffmann-La Roche Ltd (Basel, Switzerland) · Novartis AG (Basel, Switzerland) · Sanofi (Paris, France) · Pfizer Inc. (Brooklyn, New York, U.S.) · Merck & Co., Inc. (Kenilworth, New Jersey, U.S.) · GlaxoSmithKline plc (Brentford, U.K) · Alcon (Geneva, Switzerland) · Other Prominent Player